The precision medicine era has arrived and molecular profiling has become standard of care for many cancer types, recommended by the NCCN Guidelines® and required for certain therapies (companion diagnostics). More than ever, oncologists deserve a trusted profiling partner to provide reliable, high-quality molecular information to guide more precise and individualized treatment decisions.
Caris molecular profiling identifies key molecular features of cancer and provides clinical insights to aid oncologists in personalizing cancer therapies for their solid tumor cancer patients. Caris helps oncologists:
MI FOLFOXai™, the first clinically validated, AI-powered molecular predictor of chemotherapy efficacy for metastatic colorectal cancer (mCRC) patients. Gauge a mCRC patient’s likelihood of benefit from first-line FOLFOX+BV followed by FOLFIRI+BV, versus FOLFIRI+BV followed by FOLFOX+BV treatment.
Better manage cancers of unknown primary (CUP) or cases with atypical clinical presentation or clinical ambiguity to improve outcomes. MI GPSai™ analyzes genomic and transcriptomic data to match a tumor’s molecular signature across 21 cancer types from the Caris database and can help physicians and pathologists confirm tumor of origin.
The Caris Molecular Tumor Board provides the opportunity to interact with cancer experts from across the country to review molecular information on specific patient cases of a requesting oncologist. This on-demand platform enables oncologists to focus their efforts on what matters most – developing the most informed and personalized treatment strategies for their patients.
If you have questions about Caris molecular profiling please contact us today.